These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29215820)

  • 61. Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study.
    Yim HJ; Suh SJ; Jung YK; Hwang SG; Seo YS; Um SH; Lee SH; Kim YS; Jang JY; Kim IH; Kim HS; Kim JH; Lee YS; Yoon EL; Song MJ; Park JY
    J Viral Hepat; 2020 Dec; 27(12):1306-1318. PubMed ID: 32706461
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
    Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB; Kara B; Gümürdülü Y; Soylu A; Akin MS
    Turk J Gastroenterol; 2012 Jun; 23(3):247-52. PubMed ID: 22798114
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
    J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis.
    Wang HL; Lu X; Yang X; Ning Q
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):447-56. PubMed ID: 26621535
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B].
    Choi K; Lee HM; Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
    Korean J Gastroenterol; 2015 Jan; 65(1):35-42. PubMed ID: 25603852
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
    Ahn SH; Kim W; Jung YK; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Yim HJ; Lee KS; Lim YS; Lee WS; Park NH; Jin SY; Kim KH; Choi W; Han KH
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1850-1859.e4. PubMed ID: 30448598
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure.
    Lee CI; Kwon SY; Kim JH; Choe WH; Lee CH; Yoon EL; Yeon JE; Byun KS; Kim YS; Kim JH
    Gut Liver; 2014 Jan; 8(1):64-9. PubMed ID: 24516703
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
    Corsa AC; Liu Y; Flaherty JF; Mitchell B; Fung SK; Gane E; Miller MD; Kitrinos KM
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2106-12.e1. PubMed ID: 24929235
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance.
    Kim DY; Lee HW; Song JE; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    J Med Virol; 2018 Mar; 90(3):497-502. PubMed ID: 29077211
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.
    Seo YS; Kim JH; Yeon JE; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH
    World J Gastroenterol; 2007 Aug; 13(30):4072-9. PubMed ID: 17696224
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients.
    Park JW; Kwak KM; Kim SE; Jang MK; Suk KT; Kim DJ; Park SH; Lee MS; Kim HS; Park CK
    BMC Gastroenterol; 2017 Mar; 17(1):39. PubMed ID: 28279168
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
    Lim YS; Yoo BC; Byun KS; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
    Gut; 2016 Jun; 65(6):1042-51. PubMed ID: 25800784
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients.
    Yoo EH; Cho HJ
    Clin Chim Acta; 2017 Aug; 471():308-313. PubMed ID: 28687350
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
    Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
    BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
    Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
    World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.